Why the study?
While DAPT is effective for secondary prevention of coronary ischemic events and stent thrombosis, it increases major bleeding risk, making the duration of treatment a challenge.
What is the optimal duration of dual antiplatelet therapy after stent implantation to balance ischemic prevention and bleeding risk?
What is the optimal duration of dual antiplatelet therapy after stent implantation to balance ischemic prevention and bleeding risk?
This review discusses the optimal duration of dual antiplatelet therapy after stent implantation to balance ischemic protection against bleeding risks.
Short DAPT after stenting should not change practice; leaves open optimal duration amid conflicting heterogeneous trials.
Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor is the main actor in secondary prevention of recurrent coronary ischemic events and stent thrombosis. For this exact purpose the combination of two antiplatelet molecules have proven efficacy and superiority compared to monotherapy, aspirin alone, but this comes with an increased risk of major and potentially fatal bleedings, making the choice of the molecules and especially the duration of treatment a true challenge for every cardiologist. We are going to discuss some of the main factors that play a role in the decision, and the most important trials that studied the subject.
No takes yet. Share an insight, caveat, or question.
Bouraghda et al. (2024) conducted a review in Myocardial infarction or percutaneous coronary intervention (PCI). Short-duration dual antiplatelet therapy (DAPT) vs. Standard-duration DAPT (≥12 months) was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: